Floatz logo

ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)

Renal Medullary Carcinoma

Giuseppe Procopioantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Renal Medullary Carcinoma cohort.

Asset / SponsorPhaseRating
Tazemetostat
Epizyme, Inc.
Phase 2BB
Atezolizumab
National Cancer Institute (NCI)
Phase 2B
Bms-907351
National Cancer Institute (NCI)
Phase 2B
Nivolumab
National Cancer Institute (NCI)
Phase 2B
Ipilimumab
National Cancer Institute (NCI)
Phase 2B

View all 14 →

Same molecule, other indications

ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) is also rated in:

urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urinary bladder neoplasmDormant
BB
Indicative ·
68 / 100
View asset →
ureter neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →